Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

Sarah J Tabrizi; Ralph Reilmann; Raymond A C Roos; Alexandra Durr; B R Leavitt; Gail N Owen; Rebecca Jones; Hans Johnson; David O Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn

doi:10.1016/S1474-4422(11)70263-0

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

Sarah J Tabrizi, Ralph Reilmann, Raymond A C Roos, Alexandra Durr, B R Leavitt, Gail N Owen, Rebecca Jones, Hans Johnson, David O Craufurd, Stephen L Hicks, Christopher Kennard, Bernhard Landwehrmeyer, Julie C Stout, Beth Borowsky, Rachael I Scahill, Chris Frost, Douglas R Langbehn

School of Psychological Sciences

Research output: Contribution to journal › Article › Research › peer-review

448 Citations (Scopus)

Abstract

TRACK-HD is a prospective observational biomarker study in premanifest and early Huntington?s disease (HD). In this report we de? ne a battery of potential outcome measures for therapeutic trials. We assessed longitudinal data collected at baseline, 12 months, and 24 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. We estimated adjusted, between-group di?erences in rates of change in these measures and concomitant longitudinal e?ect sizes.

Original language	English
Pages (from-to)	42 - 53
Number of pages	12
Journal	The Lancet Neurology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1016/S1474-4422(11)70263-0
Publication status	Published - 2012

Access to Document

10.1016/S1474-4422(11)70263-0

Cite this

Tabrizi, S. J., Reilmann, R., Roos, R. A. C., Durr, A., Leavitt, B. R., Owen, G. N., Jones, R., Johnson, H., Craufurd, D. O., Hicks, S. L., Kennard, C., Landwehrmeyer, B., Stout, J. C., Borowsky, B., Scahill, R. I., Frost, C., & Langbehn, D. R. (2012). Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology, 11(1), 42 - 53. https://doi.org/10.1016/S1474-4422(11)70263-0

@article{590798c2e44e43ed92feab4f183cf016,

title = "Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data",

abstract = "TRACK-HD is a prospective observational biomarker study in premanifest and early Huntington?s disease (HD). In this report we de? ne a battery of potential outcome measures for therapeutic trials. We assessed longitudinal data collected at baseline, 12 months, and 24 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. We estimated adjusted, between-group di?erences in rates of change in these measures and concomitant longitudinal e?ect sizes.",

author = "Tabrizi, {Sarah J} and Ralph Reilmann and Roos, {Raymond A C} and Alexandra Durr and Leavitt, {B R} and Owen, {Gail N} and Rebecca Jones and Hans Johnson and Craufurd, {David O} and Hicks, {Stephen L} and Christopher Kennard and Bernhard Landwehrmeyer and Stout, {Julie C} and Beth Borowsky and Scahill, {Rachael I} and Chris Frost and Langbehn, {Douglas R}",

year = "2012",

doi = "10.1016/S1474-4422(11)70263-0",

language = "English",

volume = "11",

pages = "42 -- 53",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier",

number = "1",

}

Tabrizi, SJ, Reilmann, R, Roos, RAC, Durr, A, Leavitt, BR, Owen, GN, Jones, R, Johnson, H, Craufurd, DO, Hicks, SL, Kennard, C, Landwehrmeyer, B, Stout, JC, Borowsky, B, Scahill, RI, Frost, C & Langbehn, DR 2012, 'Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data', The Lancet Neurology, vol. 11, no. 1, pp. 42 - 53. https://doi.org/10.1016/S1474-4422(11)70263-0

TY - JOUR

T1 - Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

AU - Tabrizi, Sarah J

AU - Reilmann, Ralph

AU - Roos, Raymond A C

AU - Durr, Alexandra

AU - Leavitt, B R

AU - Owen, Gail N

AU - Jones, Rebecca

AU - Johnson, Hans

AU - Craufurd, David O

AU - Hicks, Stephen L

AU - Kennard, Christopher

AU - Landwehrmeyer, Bernhard

AU - Stout, Julie C

AU - Borowsky, Beth

AU - Scahill, Rachael I

AU - Frost, Chris

AU - Langbehn, Douglas R

PY - 2012

Y1 - 2012

N2 - TRACK-HD is a prospective observational biomarker study in premanifest and early Huntington?s disease (HD). In this report we de? ne a battery of potential outcome measures for therapeutic trials. We assessed longitudinal data collected at baseline, 12 months, and 24 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. We estimated adjusted, between-group di?erences in rates of change in these measures and concomitant longitudinal e?ect sizes.

AB - TRACK-HD is a prospective observational biomarker study in premanifest and early Huntington?s disease (HD). In this report we de? ne a battery of potential outcome measures for therapeutic trials. We assessed longitudinal data collected at baseline, 12 months, and 24 months at sites in Leiden (Netherlands), London (UK), Paris (France), and Vancouver (Canada). Participants were individuals without HD but carrying the mutant HTT gene (ie, premanifest HD), patients with early HD, and healthy control individuals matched by age and sex to the combined HD groups. Data were collected with 3T MRI, clinical, cognitive, quantitative motor, oculomotor, and neuropsychiatric assessments. We estimated adjusted, between-group di?erences in rates of change in these measures and concomitant longitudinal e?ect sizes.

UR - http://www.sciencedirect.com/science/article/pii/S1474442211702630

U2 - 10.1016/S1474-4422(11)70263-0

DO - 10.1016/S1474-4422(11)70263-0

M3 - Article

SN - 1474-4422

VL - 11

SP - 42

EP - 53

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 1

ER -

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

Abstract

Access to Document

Other files and links

Cite this